NYSE:LLYPharmaceuticals
Jaypirca Trial Win Highlights Eli Lilly’s Expanding Oncology Growth Story
Eli Lilly's Jaypirca (pirtobrutinib) achieved positive Phase 3 results in chronic lymphocytic leukemia and small lymphocytic lymphoma.
The late stage trial showed that Jaypirca, combined with other therapies, improved progression free survival for patients.
The data could support a regulatory submission this year to expand Jaypirca's approved uses beyond its current label.
Eli Lilly (NYSE:LLY), trading at $929.55 at the last close, is widely associated with its GLP 1 obesity and diabetes...